PMID- 30762982
OWN - NLM
STAT- MEDLINE
DCOM- 20190307
LR  - 20190307
IS  - 0047-1860 (Print)
IS  - 0047-1860 (Linking)
VI  - 65
IP  - 2
DP  - 2017 Feb
TI  - [Present and Future of an iPS Cell Stock for Regenerative Medicine].
PG  - 160-166
AB  - A haplobank of induced pluripotent stem cell (iPSC) lines derived from healthy 
      donors with homozygous human leukocyte antigen(HLA), which is called "an iPSC 
      stock", has been under construction in Japan. The iPSC stock is expected to 
      enable HLA matching of a majority of recipients and reduce the risk of trans- 
      plant rejection. Full-scale operations began in FY2013, with the aim of covering 
      30-50% of the Japanese population by FY2017 and most of the population by FY2022 
      with the iPSC stock. A novel feeder-free and xeno-free culture system for iPSCs 
      was developed to comply with regulatory safety standards. In 2015, a 
      clinical-grade iPSC line with homozygous HLA of the highest-frequency haplotype 
      was released as a first in the world. Other clinical-grade lines are being 
      generated successively. If all goes to plan, the first clinical research using 
      the iPSC stock will start in 2017. However, many challenges remain to ensuring 
      the future of iPSC stock. In accordance with the progress of the latest research, 
      safety issues regarding iPSC-based cell therapy are being monitored with much 
      interest, and one of the major concerns is tumorigenicity. We have to continue to 
      discuss the extent of genomic abnormalities that would or would not be acceptable 
      in not only iPSC-derived products but also iPSC stock, taking into account the 
      risks and benefits of cell therapy. It is also necessary to demonstrate the 
      clinical efficacy of HLA matching, which is indicated to promote graft survival 
      and reduce immunosuppressive drug use.
FAU - Hanatani, Tadaaki
AU  - Hanatani T
FAU - Takasu, Naoko
AU  - Takasu N
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Rinsho Byori
JT  - Rinsho byori. The Japanese journal of clinical pathology
JID - 2984781R
RN  - 0 (HLA Antigens)
SB  - IM
MH  - *Cell- and Tissue-Based Therapy
MH  - HLA Antigens
MH  - Humans
MH  - *Induced Pluripotent Stem Cells
MH  - Japan
MH  - *Regenerative Medicine
MH  - Safety
EDAT- 2017/02/01 00:00
MHDA- 2017/02/01 00:01
CRDT- 2019/02/15 06:00
PHST- 2019/02/15 06:00 [entrez]
PHST- 2017/02/01 00:00 [pubmed]
PHST- 2017/02/01 00:01 [medline]
PST - ppublish
SO  - Rinsho Byori. 2017 Feb;65(2):160-166.